Italia markets open in 43 minutes
Dow Jones
39.118,86 -45,24 (-0,12%) Nasdaq
17.732,60 -126,10 (-0,71%) Nikkei 225
39.604,75 +21,67 (+0,05%) EUR/USD
1,0771 +0,0055 (+0,52%) Bitcoin EUR
58.814,17 +2.407,34 (+4,27%) CMC Crypto 200
1.313,94 +11,87 (+0,91%)
Bristol-Myers Squibb Co (BRM.MU)
Munich - Munich Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 08:04AM CEST. Mercato aperto.
| Chiusura precedente | 39,01 |
| Aperto | 39,01 |
| Denaro | 38,78 x 0 |
| Domanda | 38,94 x 0 |
| Min-Max giorno | 39,01 - 39,01 |
| Intervallo di 52 settimane | 37,00 - 59,20 |
| Volume | |
| Media Volume | 28 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
© 2024 Yahoo. Tutti i diritti riservati.